Acadia Pharmaceuticals vs Alkermes
ACAD and ALKS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and ALKS compare
Alkermes is the larger company, worth 2.5 times as much as Acadia Pharmaceuticals ($8.0B against $3.2B).
On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.7× trailing earnings, against 126× for Alkermes.
Acadia Pharmaceuticals grew revenue faster over the last twelve months (14.8% versus 10.8% for Alkermes).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 30.1% compared with 4.0% at Alkermes.
Acadia Pharmaceuticals scores higher on the StockData Score (18 against 5 for Alkermes), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | ALKS |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $8.0B |
| Share price | $18.37 | $47.89 |
| Change, 1 year | −17.3% | 46.7% |
| Change, 5 years | −4.1% | 106% |
| Beta (5Y) | 0.79 | 0.41 |
| Employees | 798 | 2,050 |
| StockData Score | ||
| Total score | 18 (better) | 5 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.7× (better) | 126× |
| P/S | 2.6× (better) | 4.8× |
| P/B | 2.3× (better) | 4.4× |
| EV/EBITDA | 17.9× (better) | 49.6× |
| P/FCF | 38.6× | 36.2× (better) |
| FCF yield | 2.6% | 2.8% (better) |
| Fair value | $31.63 | $15.32 |
| Margin of safety | 41.9% (better) | −213% |
| Growth | ||
| Revenue growth (TTM) | 14.8% (better) | 10.8% |
| Revenue growth, 5Y average | 19.4% (better) | 7.3% |
| Net income growth (TTM) | 38.7% (better) | −81.0% |
| EPS growth (TTM) | 35.5% (better) | −81.7% |
| Profitability | ||
| Gross margin | 90.5% (better) | 84.6% |
| Operating margin | 10.2% (better) | 7.0% |
| Net margin | 30.1% (better) | 4.0% |
| FCF margin | 6.8% | 13.3% (better) |
| Return on equity | 31.4% (better) | 3.9% |
| Return on invested capital | 50.8% (better) | 4.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.83 (better) |
| Net debt / EBITDA | – | 4.73 |
| Interest coverage | – | 2.0× |
| Current ratio | 3.82 (better) | 2.30 |
| Altman Z-score | 4.85 (better) | 2.31 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | −1.6% | – |
| Shareholder yield | −1.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 106% |
| Held by insiders | 27.8% | 1.6% |
| Insider net buying, 12 months | −$2.5M (better) | −$10.1M |
| Short interest, % of float | 6.7% | 11.9% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- ALKS stock overview
- ALKS income statement
- ALKS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.